December 27, 2022
2 minute read
Several novel treatment regimens for prostate cancer have emerged over the past year.
Additionally, researchers highlighted the potential role of artificial intelligence in guiding treatment decisions, and hypofractionated radiation therapy emerged as a new standard for certain men.
Healio shares the following advances in prostate cancer research and treatment from the past year that may be relevant to your practice.
1. Men with high-risk prostate cancer who received a shorter course of radiation therapy had similar survival and recurrence rates as those who received a longer course of standard radiation therapy. The findings suggest that a 5-week regimen of hypofractionated radiotherapy should be a new standard for men with high-risk disease eligible for long-term external-beam radiotherapy and androgen deprivation therapy. Read more.
2. Prostate cancer clinical trials included a significant underrepresentation of Asian, black and Hispanic men based on disease incidence among these groups, according to the results of a meta-analysis published in JAMA Oncology He showed. Read more.
3. Long-acting ADT prolonged metastasis-free survival compared with short-acting ADT when added to radiation therapy after radical prostatectomy, the randomized phase 3 results showed. Read more.
Four. Enzalutamide monotherapy (Xtandi; Astellas, Pfizer) induced a significant response to treatment among men on active surveillance for low- or intermediate-risk localized prostate cancer. Read more.
5. FDA-approved darolutamide (Nubeqa, Bayer) tablets in combination with docetaxel for men with hormone-sensitive metastatic prostate cancer. Read more.
6. PSA testing appeared to be associated with lower prostate cancer-specific mortality among black men and non-Hispanic white men. Read more.
7. Preoperative MRI led to significantly fewer postoperative complications among men who underwent prostatectomy. Read more.
8. The addition of ADT to radiation therapy improved survival among men with localized prostate cancer. Read more.
9. The FDA approved Lu 177 vipivotide tetraxetan lutetium (Pluvicto, Novartis) for the treatment of certain men with advanced prostate cancer. Read more.
10 Increases in the incidence of metastatic prostate cancer may be temporarily associated with changes in clinical policy following the recommendations of the US Preventive Services Task Force. Read more.
eleven The addition of darolutamide to ADT and docetaxel prolonged OS among men with metastatic hormone-sensitive prostate cancer. Read more.
12 An AI-derived digital pathology-based biomarker (ArteraAI-Predict ADT) may help guide treatment decisions for men with localized intermediate-risk prostate cancer. Read more.
13 The addition of niraparib (Zejula) to abiraterone acetate (Zytiga, Janssen) and prednisone improved outcomes for certain men with prostate cancer. Read more.
14 The addition of olaparib (Lynparza; AstraZeneca, Merck) to abiraterone acetate (Zytiga, Janssen) significantly prolonged radiographic PFS in first-line treatment for metastatic castration-resistant prostate cancer. Read more.